XORTX Therapeutics Inc. (NASDAQ:XRTX) Announces Reverse Stock Split and Pipeline Progress
XORTX Therapeutics (US:XRTX) Financial Modeling Prep·2026-03-30 19:05(NASDAQ:XRTX) is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. The company has three advanced clinical products in its pipeline: XRx-026 for gout treatment, XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for acute kidney and other organ injuries related to respiratory virus infections. XRTX is preparing for a reverse stock split scheduled for April 6, 2026. This event will consolidate shares at ...